Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03080974
PHASE2
Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
Sponsor: University of Louisville
View on ClinicalTrials.gov
Summary
Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2017-08-14
Completion Date
2029-04-01
Last Updated
2025-10-29
Healthy Volunteers
No
Conditions
Interventions
DRUG
Nivolumab
Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
PROCEDURE
Irreversible Electroporation
Non-thermal ablation of tumor
Locations (1)
University of Louisville
Louisville, Kentucky, United States